Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H. Ishikawa Y, et al. Among authors: togitani k. Blood Adv. 2020 Jan 14;4(1):66-75. doi: 10.1182/bloodadvances.2019000709. Blood Adv. 2020. PMID: 31899799 Free PMC article.
Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia.
Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, Sakamaki H, Kouzai Y, Kasai M, Fukuda T, Azuma H, Takanashi M, Okamoto S, Tsuchida M, Kawa K, Morishima Y, Kodera Y, Kato S; Japan Cord Blood Bank Network. Atsuta Y, et al. Blood. 2009 Feb 19;113(8):1631-8. doi: 10.1182/blood-2008-03-147041. Epub 2008 Dec 22. Blood. 2009. PMID: 19104080 Free article. Clinical Trial.
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.
Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, Miyata Y, Kobayashi S, Usuki K, Matsumura I, Minami Y, Usui N, Fukuda T, Takada S, Ishikawa M, Fujimaki K, Gomyo H, Sasaki O, Ohishi K, Miyake T, Imai K, Suzushima H, Mitsui H, Togitani K, Kiguchi T, Atsuta Y, Ohtake S, Ohnishi K, Kobayashi Y, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group. Takahashi N, et al. Among authors: togitani k. Int J Hematol. 2018 Feb;107(2):185-193. doi: 10.1007/s12185-017-2334-x. Epub 2017 Sep 19. Int J Hematol. 2018. PMID: 28929332 Clinical Trial.
Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.
Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T; New TARGET investigators. Kizaki M, et al. Int J Hematol. 2019 Apr;109(4):426-439. doi: 10.1007/s12185-019-02613-1. Epub 2019 Feb 14. Int J Hematol. 2019. PMID: 30762219 Clinical Trial.
Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.
Murata M, Suzuki R, Nishida T, Shirane S, Shimazu Y, Minami Y, Mori T, Doki N, Kanda Y, Uchida N, Tanaka M, Ishikawa J, Togitani K, Fukuda T, Ichinohe T, Atsuta Y, Nagamura-Inoue T, Kiyoi H. Murata M, et al. Among authors: togitani k. Intern Med. 2020;59(16):1947-1956. doi: 10.2169/internalmedicine.4375-19. Epub 2020 Aug 15. Intern Med. 2020. PMID: 32801269 Free PMC article.
AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP, Taguchi H, Yokoyama A. Yang J, et al. Among authors: togitani k. Blood. 2007 Sep 15;110(6):2034-40. doi: 10.1182/blood-2007-02-073700. Epub 2007 May 10. Blood. 2007. PMID: 17495131 Free article.
The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis.
Nishimori H, Matsuo K, Maeda Y, Nawa Y, Sunami K, Togitani K, Takimoto H, Hiramatsu Y, Kiguchi T, Yano T, Yamane H, Tabayashi T, Takeuchi M, Makita M, Sezaki N, Yamasuji Y, Sugiyama H, Tabuchi T, Kataoka I, Fujii N, Ishimaru F, Shinagawa K, Ikeda K, Hara M, Yoshino T, Tanimoto M; West-Japan Hematology and Oncology Group (West-JHOG). Nishimori H, et al. Among authors: togitani k. Int J Hematol. 2009 Apr;89(3):326-331. doi: 10.1007/s12185-009-0259-8. Epub 2009 Mar 27. Int J Hematol. 2009. PMID: 19326060
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, Shimomura T, Isobe Y, Oshimi K, Dan K, Ohyashiki K, Ikeda Y; TARGET Investigators. Tauchi T, et al. Leuk Res. 2011 May;35(5):585-90. doi: 10.1016/j.leukres.2010.10.027. Epub 2010 Dec 10. Leuk Res. 2011. PMID: 21145591
54 results